PhaseBio Pharmaceuticals Inc
OTC:PHASQ

Watchlist Manager
PhaseBio Pharmaceuticals Inc Logo
PhaseBio Pharmaceuticals Inc
OTC:PHASQ
Watchlist
Price: 0.0001 USD
Market Cap: 49.9 USD

Operating Margin
PhaseBio Pharmaceuticals Inc

-991.3%
Current
-9 731%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-991.3%
=
Operating Profit
-107.4m
/
Revenue
10.8m

Operating Margin Across Competitors

No Stocks Found

PhaseBio Pharmaceuticals Inc
Glance View

Market Cap
49.9 USD
Industry
Biotechnology

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiopulmonary diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2018-10-18. The Company’s product pipeline includes Bentracimab (PB2452), PB6440 (for treatment-resistant Hypertension), pemziviptadil (PB1046), GLP2-ELP and CNP-ELP. The firm conducting REVERSE-IT, its pivotal Phase III clinical trial of bentracimab. PB2452 is a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor in the event of major bleeding. PB6440 is an oral selective aldosterone synthase inhibitor for treatment of resistant hypertension. Pemziviptadil (PB1046), is a novel, subcutaneously-injected VIP analogue, which is a recombinant fusion protein composed of VIP and its proprietary ELP technology. ELP technology platform is a growth engine for additional medicines for cardiovascular diseases.

PHASQ Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-991.3%
=
Operating Profit
-107.4m
/
Revenue
10.8m
What is the Operating Margin of PhaseBio Pharmaceuticals Inc?

Based on PhaseBio Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of -991.3%.

Back to Top